Found this stock over the past weekend, and it definitely looks promising.
This stock could take an OTC-like hyperbolic trajectory if their technology ends up working, and I'm inclined to believe (and hope) it will.
Only thing I'm concerned about short term is the currently rich valuation based on little to no revs, what looks like a loss in some grant funding year over year, and some dilution. ...
But I read somewhere that this company has enough $ on the books to get them to 2015, and its encouraging to see their product testing is ahead of schedule and revs could start coming in before the end of this year.
More to your point.... IMO the company just released some good news in that their inhouse testing went well and concluded faster than expected.
Next significant news is the response from the KOL (whose name I wish were revealed but oh well). The stuff like this conference invite is interesting but I doubt will affect the PPS too much.
GLTA, I hope this ends up making longs a lot of money, and that this company changes the game in organ and tissue repair/transplantation!
Market Data 
Markets 
AI
